Question to the Department of Health and Social Care:

To ask His Majesty's Government, further to the Written Answer by Lord Markham on 1 February (HL4939), when the figures referred to in the Written Answer on 12 April 2022 (HL7711), which provide the number of clinically extremely vulnerable individuals who do not make antibodies through the vaccinations currently available but who would be protected by pre-exposure prophylaxis from monoclonal antibodies, will be updated.

The Independent Advisory Group produced a report in July 2022 identifying a prioritised list of people with conditions for which it may be clinically advantageous to receive neutralising monoclonal antibodies prophylaxis, which was submitted to the National Institute for Health and Care Excellence (NICE) as part of their Health Technology Evaluation of Evusheld. A copy of NICE’s committee paper, published 16 February 2023, is attached, see Pages 972 – 987.